Patents by Inventor Bela Anand-Apte

Bela Anand-Apte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TIMP3 AS VEGF INHIBITOR
    Publication number: 20170137495
    Abstract: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).
    Type: Application
    Filed: November 21, 2016
    Publication date: May 18, 2017
    Inventor: Bela Anand-Apte
  • TIMP3 as VEGF inhibitor
    Patent number: 9498509
    Abstract: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: November 22, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventor: Bela Anand-Apte
  • Compositions And Methods For Macular Degeneration
    Publication number: 20160108114
    Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 21, 2016
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
  • Anti-angiogenic peptides
    Patent number: 8431396
    Abstract: A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: April 30, 2013
    Assignee: The Cleveland Clinic Foundation
    Inventor: Bela Anand-Apte
  • Compositions And Methods For Macular Degeneration
    Publication number: 20120230996
    Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
    Type: Application
    Filed: February 9, 2012
    Publication date: September 13, 2012
    Applicant: The Cleveland Clinic Foundation and Case Western Reserve University
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
  • Methods of reducing angiogenesis of age-related macular degeneration (AMD) or choroidal neovascularization by an anti-carboxyetheylpyrrole (CFP) antibody
    Patent number: 8137991
    Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: March 20, 2012
    Assignees: The Cleveland Clinic Foundation, Case Western Reserve University
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Reganathan
  • COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION
    Publication number: 20100143380
    Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.
    Type: Application
    Filed: July 23, 2007
    Publication date: June 10, 2010
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
  • ANTI-ANGIOGENIC PEPTIDES
    Publication number: 20100099611
    Abstract: A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.
    Type: Application
    Filed: February 29, 2008
    Publication date: April 22, 2010
    Inventor: Bela Anand-Apte
  • TIMP3 as VEGF inhibitor
    Publication number: 20070202094
    Abstract: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).
    Type: Application
    Filed: January 16, 2007
    Publication date: August 30, 2007
    Inventor: Bela Anand-Apte
  • TIMP3 as VEGF inhibitor
    Patent number: 7183256
    Abstract: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF recptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: February 27, 2007
    Assignee: Cleveland Clinic Foundation
    Inventor: Bela Anand-Apte
  • TIMP3 as VEGF inhibitor
    Publication number: 20040224398
    Abstract: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF recptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).
    Type: Application
    Filed: March 19, 2004
    Publication date: November 11, 2004
    Applicant: The Cleveland Clinic Foundation
    Inventor: Bela Anand-Apte